Vivo Capital’s Larimar Therapeutics LRMR Stock Holding History

Vivo Capital’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-399,830	Closed	-$4.31M	–	56
2021 Q4	$4.31M	Hold	399,830	–	–	0.26%	48
2021 Q3	$4.61M	Sell	399,830 -399,832	-50%	-$4.8M	0.21%	52
2021 Q2	$7.85M	Hold	799,662	–	–	0.34%	47
2021 Q1	$11.7M	Hold	799,662	–	–	0.41%	39
2020 Q4	$17.1M	Hold	799,662	–	–	0.76%	30
2020 Q3	$12.1M	Hold	799,662	–	–	0.7%	38
2020 Q2	$10.3M	Buy	+799,662	New	+$9.31M	0.74%	31

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

Vivo Capital's LRMR Position: Q1 2022 in Review

Vivo Capital sold out of Larimar Therapeutics (LRMR) in Q1 2022, closing a stake of 399,830 shares — an estimated $4.31M sold.

Vivo Capital first reported a position in LRMR in Q2 2020 and held it in 7 quarters. The position peaked at $17.1M in Q4 2020. 45 funds tracked by Wall St. Rank hold LRMR as of Q1 2022.

Vivo Capital reported no remaining Larimar Therapeutics position as of Q1 2022 after selling out during the quarter.
Vivo Capital sold 399,830 Larimar Therapeutics shares in Q1 2022, an estimated $4.31M.
Vivo Capital first reported a position in Larimar Therapeutics in Q2 2020 and held it in 7 quarters.
Vivo Capital's Larimar Therapeutics position peaked at $17.1M in Q4 2020.
45 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2022.

Based on Vivo Capital's 13F filing for Q1 2022, filed 13 May 2022.